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Introduction
DNA replication occurs once per cell cycle. Tight regulation of 
this process is controlled by the replication licensing machinery 
through periodic accumulation and destruction of the prerepli-
cative complex (pre-RC), including among others, the Cdc6 (cell 
division cycle 6) protein (Lau et al., 2007; Borlado and Méndez, 
2008). Cdc6 is a 60-kD protein that belongs to the AAA+ 
(ATPases associated with various activities) family of ATPases 
(Borlado and Méndez, 2008; Zachariadis and Gorgoulis, 
2008). Deranged expression of pre-RC proteins, such as over-
expression of Cdc6, leads to rereplication (Vaziri et al., 2003; 
Bartkova et al., 2006; Davidson et al., 2006; Liontos et al., 
2007; Blow and Gillespie, 2008; Green et al., 2010), a form of 
replication stress, fuelling genomic instability, and promoting 
malignant behavior (Karakaidos et al., 2004; Liontos et al., 
2007; Halazonetis et al., 2008; Negrini et al., 2010, Hanahan 
and Weinberg, 2011). In addition to this tumorigenic mecha-
nism, Cdc6 has been reported to exert its oncogenic activity 
E-cadherin (CDH1) loss occurs frequently in carcino-genesis, contributing to invasion and metastasis. We observed that mouse and human epithelial cell 
lines overexpressing the replication licensing factor Cdc6 
underwent phenotypic changes with mesenchymal fea-
tures and loss of E-cadherin. Analysis in various types 
of human cancer revealed a strong correlation between 
increased Cdc6 expression and reduced E-cadherin levels. 
Prompted by these findings, we discovered that Cdc6 re-
pressed CDH1 transcription by binding to the E-boxes of 
its promoter, leading to dissociation of the chromosomal 
insulator CTCF, displacement of the histone variant 
H2A.Z, and promoter heterochromatinization. Mutational 
analysis identified the Walker B motif and C-terminal 
region of Cdc6 as essential for CDH1 transcriptional 
suppression. Strikingly, CTCF displacement resulted in 
activation of adjacent origins of replication. These data 
demonstrate that Cdc6 acts as a molecular switch at the 
E-cadherin locus, linking transcriptional repression to 
activation of replication, and provide a telling example 
of how replication licensing factors could usurp alterna-
tive programs to fulfill distinct cellular functions.
Cdc6 expression represses E-cadherin transcription 
and activates adjacent replication origins
Maria Sideridou,1 Roubini Zakopoulou,1 Konstantinos Evangelou,1 Michalis Liontos,1 Athanassios Kotsinas,1 
Emmanouil Rampakakis,2,3 Sarantis Gagos,4 Kaoru Kahata,6 Kristina Grabusic,8 Kalliopi Gkouskou,9,10  
Ioannis P. Trougakos,11 Evangelos Kolettas,12,13 Alexandros G. Georgakilas,14 Sinisa Volarevic,7  
Aristides G. Eliopoulos,9,10 Maria Zannis-Hadjopoulos,2,3 Aristidis Moustakas,6,7 and Vassilis G. Gorgoulis1,5
1Molecular Carcinogenesis Group, Department of Histology and Embryology, School of Medicine, University of Athens, 11527 Athens, Greece
2Goodman Cancer Center and 3Department of Biochemistry, McGill University, Montreal, Quebec H3G 1Y6, Canada
4Laboratory of Genetics, 5Biomedical Research Foundation, Academy of Athens, 11527 Athens, Greece
6Ludwig Institute for Cancer Research, Biomedical Center; and 7Department of Medical Biochemistry and Microbiology, Science for Life Laboratory;  
Uppsala University, SE-751 23 Uppsala, Sweden
8Department of Molecular Medicine and Biotechnology, School of Medicine, University of Rijeka, HR-51000 Rijeka, Croatia
9Molecular and Cellular Biology Laboratory, Division of Basic Sciences, University of Crete Medical School, 71003 Heraklion, Crete, Greece
10Institute for Molecular Biology and Biotechnology, Foundation of Research and Technology–Hellas, GR-70013 Heraklion, Crete, Greece
11Department of Cell Biology and Biophysics, Faculty of Biology, University of Athens, GR-15784 Athens, Greece
12Cell and Molecular Physiology Unit, Department of Physiology, School of Medicine, University of Ioannina, 45110 Ioannina, Greece
13Biomedical Research Institute, Foundation of Research and Technology–Hellas (FORTH), GR-45110 Ioannina, Greece
14Department of Biology, Thomas Harriot College of Arts and Sciences, East Carolina University, Greenville, NC 27858
© 2011 Sideridou et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the pub-
lication date (see http://www.rupress.org/terms). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, 
as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
IO
L
O
G
Y
JCB • VOLUME 195 • NUMBER 7 • 2011 1124
Cdc6 and E-cadherin expression was also apparent in various 
human tumors, as depicted by serial section immunohisto-
chemical analysis (Fig. 3, Table S1, and Table S2). The cor-
responding adjacent normal epithelia served as negative and 
positive internal controls for Cdc6 (Liontos et al., 2007) and 
E-cadherin, respectively (Fig. 3).
In support of the central role of Cdc6 in CDH1 regula-
tion, siRNA-mediated Cdc6 silencing reestablished the epithe-
lial, E-cadherin–positive phenotype (Fig. 4, a and b). This was 
also shown in A549 cells expressing a tetracycline-inducible 
Cdc6. Upon Cdc6 induction, the cells attained a mesenchymal 
E-cadherin–negative phenotype, which was reversed (MET) 
when exogenous Cdc6 expression was switched off (Fig. 4 c). 
From the aforementioned findings, we conclude that E-cadherin 
suppression by Cdc6 (reversible change) is independent from 
Cdc6-driven genetic (irreversible) alterations. The ability of 
increased Cdc6 expression to trigger genomic instability was 
confirmed in the present study, in line with previous studies 
(see Introduction, Fig. S1, and Fig. S2). In comparison with 
the morphological changes that occurred within a short time 
period (Fig. 4), genomic instability was evident only after a 
longer period of cultivation (Fig. S1 and Fig. S2). A notewor-
thy observation of our molecular cytogenetic analysis was that 
the p53 locus suffered allelic loss in both P1 and A549 Cdc6-
tranformed cells (Fig. S2 c).
Collectively, these data demonstrate a novel role for Cdc6 
as a negative regulator of E-cadherin expression. Subsequently, 
the mechanism underlying E-cadherin down-regulation by 
Cdc6 was addressed.
Cdc6 represses E-cadherin by  
binding directly to the E-boxes of the 
CDH1 promoter
Transient expression of Cdc6 was followed by reduction of 
E-cadherin at the protein and mRNA level in all cell lines in-
vestigated (P1, MCF7A, MDCK, and immortalized human 
bronchial epithelial [HBEC3-KT] cells; Fig. 5), suggesting that 
regulation occurs at the transcriptional level. The latter was 
further examined with a luciferase reporter harboring 1.484 kb 
of 5-flanking sequences, spanning the regulatory elements of 
CDH1 (Fig. 6 a; Peinado et al., 2004; Berx and van Roy, 2009). 
The activity of the CDH1 promoter-driven luciferase reporter 
showed a significant decrease when cotransfected with Cdc6 
(Fig. 6 a). The extent of reduction was slightly higher than that 
obtained by a reporter driven by the regulatory domain (RD) of 
INK4/ARF used as a positive control (Fig. 6 a; Gonzalez et al., 
2006). This RD element was identified during an experimental 
survey for regulatory elements proximal to replication origins 
of the INK4A/ARF locus. It turned out to be conserved in mam-
mals and to coincide with a replication origin 1.5 kb upstream 
of this locus. Based on the aforementioned observations and 
because tethering of Cdc6 to DNA stimulates pre-RC assembly 
and replication initiation (Takeda et al., 2005), we searched for 
origins adjacent to the CDH1 promoter that could also act as 
regulatory elements. To this end, we quantified nascent DNA 
products in a 10-kb region flanking it, in both P1 and A549 
lines. Interestingly, abundant nascent DNA levels originating 
by repressing the INK4/alternative reading frame (ARF) locus 
(Gonzalez et al., 2006).
We have previously made the intriguing observation that 
Cdc6 overexpression in premalignant, nontumorigenic mouse 
epithelial cells leads to malignant transformation with features 
of epithelial to mesenchymal transition (EMT; Liontos et al., 
2007). EMT is vital for tissue morphogenesis: it is pathologi-
cally activated in cancer and is marked by loss of the tumor 
suppressor E-cadherin (Hirohashi, 1998; Thiery et al., 2009). 
E-cadherin (CDH1) belongs to the superfamily of Ca2+-dependent 
homophilic adhesion molecules. It is localized, together with 
the catenin complex, to the adherens junctions organizing inter-
epithelial attachments (Hirohashi, 1998). Loss of E-cadherin 
expression follows the Knudson “two-hit” inactivation process 
of tumor suppressor genes in various (familial and nonfamilial) 
types of cancer and is associated with cancer invasion (Hirohashi, 
1998). Biallelic inactivation involves combinations between 
mutations, deletions, aberrant endocytosis–proteolytic process-
ing, and epigenetic silencing, with the last being a prominent 
event (Berx and van Roy, 2009 and references therein). Of note, 
in familial malignancies, such as diffuse gastric and lobular 
breast cancer, germline mutations are frequently complemented 
by CDH1 promoter hypermethylation (Berx and van Roy, 2009 
and references therein).
Our observations (Liontos et al., 2007) led us to hypothe-
size that tumorigenic Cdc6 may repress the CDH1 locus. Here, 
we report a novel mechanism of E-cadherin suppression, medi-
ated by Cdc6, which disrupts epithelial integrity and activates 
adjacent replication origins.
Results
Oncogenic Cdc6 represses E-cadherin
Extending our previous findings in P1 mouse cells (Liontos 
et al., 2007), we have found that stable expression of Cdc6 in 
A549 human lung carcinoma cells also results in loss of epithe-
lial characteristics and acquirement of a mesenchymal pheno-
type (Fig. 1 a). Thus, Cdc6-transformed P1 and A549 cells 
displayed loss of membranous E-cadherin (Fig. 1, a and b), up-
regulation of the mesenchymal markers, N-cadherin, vimentin, 
and fibronectin (Fig. 1 a), and a shift of membranous -catenin 
to the cytoplasm and nucleus (Fig. 1 b). As a control (Gonzalez 
et al., 2006), INK4 levels were also decreased in P1-Cdc6 
cells (Fig. 1 b).
The Cdc6-transfected cells migrated and proliferated 
faster than their control (Mock) counterparts (Fig. 1, c and d), 
were more invasive, and formed larger and more colonies in 
soft agar (Fig. 1, e and f). Grafted A549-Cdc6 cells gener-
ated tumors in severe combined immunodeficiency (SCID) 
mice faster than control counterparts (Fig. 2 a). In addition, 
only the P1-Cdc6 cells formed tumors, as the P1 control 
cells are nontumorigenic (Fig. 2 b). Cdc6-driven tumors were 
almost completely E-cadherin negative and demonstrated 
predominantly mesenchymal features, such as spindle cell 
morphology and a partial (in A549-Cdc6) or complete 
(in P1-Cdc6) intermediate filament shift from cytokeratin to 
vimentin (Fig. 2). Importantly, the inverse connection between 
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Cdc6 could directly suppress CDH1 by binding to the CDH1  
promoter E-boxes. Indeed, Cdc6 expression decreased CDH1 
promoter-driven luciferase reporter activity in various cell 
lines, whereas a promoter construct carrying mutated E-boxes 
remained unresponsive (Fig. 6 e). To further validate this find-
ing we generated recombinant full-length Cdc6 protein 
(Fig. S4, a–c) and tested its capacity to bind to the E-box sequence. 
Using electrophoretic mobility shift assays (EMSAs), we found 
that recombinant Cdc6 binds specifically to the wild-type 
E-box element but not to a mutated E-box (Fig. 6 f). Moreover, 
a specific band shift was noticed when protein extracts from 
the Cdc6-transformed cells, but not from the control (Mock) 
ones, were incorporated in a reaction containing the E-box 1 
and E-pal elements (palindromic sequence composed of two 
adjacent E-boxes of the mouse CDH1 promoter; Peinado 
et al., 2004) of the human and mouse E-cadherin promoters, 
from a single region immediately next to the CDH1 promoter 
were uncovered (position 495 in P1 cells and 286 in A549; 
Fig. 6, b and c; Fig. S3; and Table S4). Of note, P1-Cdc6 cells 
exhibited activation of a dormant origin of replication because 
almost no nascent DNA originated from this site in Mock cells 
(Fig. 6 b and Fig. S3). However, an enhancement of the already 
active replication origin was found in A549-Cdc6 transfectants 
(Fig. 6 c and Fig. S3).
In contrast to the RD element, which is conserved 
among mammals, the human and mouse CDH1 replication 
origins do not show any sequence similarities. Yet, sequence 
alignment of the RD element and the CDH1 promoter identi-
fied conservation of the consensus CANNTG motif (Fig. 6 d). 
Intriguingly, this element matches the E-box sequence, the 
major cis-acting negative regulatory element of CDH1 (Hajra 
et al., 1999; Li et al., 2000). We therefore reasoned that 
Figure 1. Overexpression of Cdc6 represses E-cadherin. (a) Loss of membranous localization, decreased expression of E-cadherin (E-cad), and spindle 
morphology in A549-Cdc6 cells. The mesenchymal markers N-cadherin (N-cad), vimentin (vim), and fibronectin (FN) are up-regulated and accompany 
Cdc6 overexpression. (b) Similar morphological features and E-cadherin loss appear in P1-Cdc6 cells along with decreased p16INK4A and p19ARF levels. 
Ultrastructural features, such as loss of desmosomes (circled inset photo) and elongated shape, further confirm morphological changes. Shift of membranous 
(Memb) -catenin (-cat) to the cytoplasm (Cyt) and nucleus (Nucl) of Cdc6 cells. Because the INK4 locus is deleted in A549 cells (Pineau et al., 2003), 
the impact of Cdc6 overexpression on INK4 products could not be determined. (c) A549- and P1-hCdc6 cells migrate faster than corresponding control 
(Mock) cells for the indicated time points after an induced scratch. (d) Cdc6 overexpression confers a growth advantage to P1 and A549 cells. (i and iv) 
Growth curves of A549- and P1-Cdc6 Mock and parental (Prl) cells (*, P ≤ 0.01). (ii–vi) Tables depict FACS results (ii and v), whereas line plots show BrdU 
incorporation of the same P1- and A549-Cdc6 cells (iii and vi) in comparison with their corresponding control (Mock) cells (*, P ≤ 0.01). (e) A549-Cdc6 
cells are more invasive in the matrigel assay than the corresponding A549-Mock cells. Mean values from triplicate fields are plotted with SDs (*, P < 0.05). 
(f) A549-Cdc6 clones form more and larger colonies than the A549-Mock cells in soft agar assay (P < 0.001). Molecular markers are given in kilodaltons.
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Figure 2. Tumor formation of grafted A549- and P1-Cdc6 cells in SCID mice. (a) Subcutaneously injected A549-Cdc6 cells form faster tumors than the 
Mock cells. Graph shows a single round of five animals (7-wk-old male SCID mice) per each cell type, which were subcutaneously injected on the left dorsal 
flank. Presence of E-cadherin and cytokeratin staining in A549-Mock–derived tumors. Absence of E-cadherin and partial intermediate filament shift from 
cytokeratin to vimentin in tumors generated from A549-Cdc6–grafted cells in SCID mice. The asterisk denotes a statistically significant result. (b) Only the 
P1-Cdc6 cells formed tumors because the P1-Mock cells are nontumorigenic. Graph shows a single round of five animals (7-wk-old male SCID mice) per 
each cell type, which were subcutaneously injected at two sites in the abdominal region. Absence of E-cadherin and complete intermediate filament shift 
from cytokeratin to vimentin in tumors generated from P1-Cdc6–grafted cells in SCID mice. Insets depict magnifications of the dotted rectangular areas. 
Error bars indicate SDs (*, P < 0.01).
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control, whereas distal regions served as negative controls 
(Fig. 7 a, left box and top right box, respectively). It has re-
cently been reported that the epigenetic silencing of the tumor 
suppressor genes p16INK4A, RASSF1A, and CDH1 depends on 
the binding of the CTCF insulator to chromosomal boundar-
ies, acting as a barrier against the spread of heterochromatin 
(Witcher and Emerson, 2009). In silico analysis using the 
CTCFBSDB tool (Bao et al., 2008) indicated the presence of 
CTCF binding sites in the human and mouse CDH1 promot-
ers. Sequence alignment of the mouse and human CDH1 pro-
moter regions showed that in both species the CTCF regulatory 
sites colocalize with the E-pal and the E-box 1, respectively 
(Fig. 7 b). Moreover, a recent study reported that CTCF bind-
ing sites are flanked by nucleosomes enriched for the histone 
variant H2A.Z, which possesses an antisilencing role (Fu 
et al., 2008). Prompted by these observations, we tested 
whether Cdc6 removes CTCF and H2A.Z from the CDH1 pro-
moter, promoting heterochromatization of the region. Indeed, 
ChIP analysis revealed that CTCF and H2A.Z were displaced 
respectively (Fig. S4, d and e; and Table S5). Competition 
with molar excess of unlabeled, but mutated, E1-box and E-pal 
elements did not affect binding, whereas the band was super-
shifted when an N-terminal anti-Cdc6 antibody was included 
in the reaction mixture, confirming the presence of Cdc6 in the 
DNA–protein complex (Fig. S4, d and e). We conclude that 
the binding of Cdc6 to E-boxes associates with its capacity to 
suppress CDH1 transcriptional activation.
Binding of Cdc6 to the E-boxes displaces 
the chromosomal insulator CTCF and 
histone H2A.Z triggering CDH1  
promoter heterochromatization
In line with the EMSA data, chromatin immunoprecipitation 
(ChIP) assays in Cdc6-transformed cells demonstrated binding 
of myc-tagged Cdc6 to the chromatin regions containing the 
E-pal element and the E-boxes 1 and 3 from the mouse and 
human CDH1 promoter, respectively (Fig. 7 a, middle box; 
and Table S3). The RDINK4A/ARF element was used as a positive 
Figure 3. Inverse relationship between E-cadherin and Cdc6 expression in human tumors. Immunohistochemical analysis on serial sections from human 
lung, laryngeal, colon, and gastric carcinomas. Graphs plot the number of individual human tumors that exhibit membranous E-cadherin versus cyto-
plasmic/reduced E-cadherin and their relation to the levels (OE, overexpressed; NE, normal expression) of Cdc6 (*, P < 0.001). Corresponding normal 
epithelia that serve as internal positive controls for E-cadherin and negative controls for Cdc6 in relation to their corresponding adjacent carcinomas are 
also shown.
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shutting down E-cadherin expression. Further support for 
this novel mechanistic model emerges from the fact that 
siRNA silencing of CTCF represses E-cadherin transcrip-
tion (Fig. 7 c).
The Walker B motif and C-terminal  
region of Cdc6 are essential for  
CDH1 suppression
Sequencing of Cdc6 in tumors has so far failed to identify 
mutations, implying that its structural integrity is vital for 
its function (Blow and Gillespie, 2008). Cdc6 includes sev-
eral conserved and functionally important motifs (Borlado and 
Méndez, 2008; Zachariadis and Gorgoulis, 2008). The N terminus 
from the CDH1 promoter in Cdc6-transformed cells (Fig. 7 a, 
middle box). These chromatin modifications were accompanied 
by hypoacetylation of histones H3 and H4 (Fig. 7 a, middle box), 
suggesting a histone deacetylase recruitment in the region en-
closing the E-boxes. Treatment with the histone deacetylase 
inhibitor trichostatin A (TSA) prevented Cdc6-induced deacety-
lation of the CDH1 promoter, supporting this notion (Fig. 7 a, 
bottom right box). Subsequently, signs of heterochromatinization, 
as depicted by increased H3K9me3, were identified (Fig. 7 a, mid-
dle box). Similar results were obtained after transient expression 
of myc-tagged Cdc6 in MCF7A cells (Fig. 7 a, middle box).
Overall, these data clearly support a model in which bind-
ing of Cdc6 is followed by regional chromatin reorganization 
Figure 4. Cdc6-mediated E-cadherin suppression is reversible. (a) Cdc6 siRNA in A549-Cdc6 cells restored the epithelial E-cadherin (E-Cad)–positive 
phenotype. (b) Similar effect in P1-Cdc6 cells. (c and d) Induction of Cdc6 expression in the A549–Tet-ON–inducible cells (for 3 d) led to E-cadherin down-
regulation and to a spindle phenotype that are reversed after shutting down Cdc6 (for an additional 5 d). A549–Tet-ON Cdc6 low density cells were 
continuously passaged to avoid aggregation. ctrsi, control siRNA. Molecular markers are given in kilodaltons.
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(Fig. 8, e and f). Collectively, the functional analysis of the 
Cdc6 mutants revealed that the Walker B motif and C-terminal 
portion of Cdc6 are indispensable for CDH1 suppression.
Displacement of CTCF by Cdc6 links 
transcriptional repression of CDH1 with 
activation of adjacent replication origins
Cancer adopts embryonic programs, such as EMT, necessary for 
its progression. Moreover, changes in origin selection, localiza-
tion, and temporal activation occur during embryonic develop-
ment and are often linked to gene expression (Norio et al., 2005; 
Grégoire et al., 2006). Given that CDH1 suppression is essential 
for EMT, colocalization of genes, such as CDH1 and INK4/ARF, 
with origins of replication implies a mutually exclusive func-
tional relationship between replication firing and activation of 
genes related with growth inhibition and/or differentiation. We 
therefore asked whether Cdc6-mediated E-cadherin suppression 
and Cdc6-triggered activation of the adjacent replication origins 
are intertwined or whether they are coincidental.
Using the tetracycline-regulated Cdc6 in A549 cells, we 
observed down-regulation of E-cadherin upon induction of 
Cdc6, which was accompanied by a threefold enhancement 
of replication origin activity. Conversely, shutting down Cdc6 
was followed by reestablishment of E-cadherin and decreased 
activity of the replication origin (Fig. 9 a). Notably, Cdc6 over-
expression only marginally increased the activities of the rep-
lication origins of the Lamin B2 and HPRT genes, which were 
used as positive controls (Fig. 6, b and c; Falaschi et al., 2007), 
suggesting that oncogenic Cdc6 does not activate all origins 
uniformly but targets specific replication sites.
The binding activity of CTCF to the CDH1 promoter 
followed the fluctuations of the E-cadherin levels (Fig. 9 b). 
contains three consensus phosphorylation sites at S54, S74, 
and S106, which are nodal for Cdc6 protein turnover (Fig. 8 a). 
Mutating S54, S74, and S106 to alanines (Cdc6-AAA) or 
truncating the N terminus (125-Cdc6/NH2-Cdc6; Fig. 8 a) 
partly compromised the suppressive effect on CDH1 (Fig. 8 b), 
whereas these mutations had no effect on INK4 repression 
(Gonzalez et al., 2006). Of note, removal of the N-terminal 
125–amino acid region (125) produced a nondegradable 
form of Cdc6, which however, was unable to suppress CDH1 
to the extent that wild-type Cdc6 did (Fig. 8 b). Therefore, 
the N-terminal region possesses features that influence the 
chromatin-remodeling capacity of Cdc6.
The central portion of Cdc6 harbors the Walker A (amino 
acids 202–209) and Walker B (amino acids 284–287) motifs, 
which bind and hydrolyze ATP, respectively. Substituting 
D284A and D285A in the Walker B motif (Cdc6-WB) almost 
abolished the suppressive effect on CDH1 expression (Fig. 8 b).
The C-terminal Cdc6 domain encompasses among others 
a conserved winged helix domain that is present in several 
DNA-binding proteins (Borlado and Méndez, 2008). Deleting 
the C-terminal domain (440–560) of Cdc6 (Cdc6-COOH; 
Fig. 8 a) abolished the suppressive effect on CDH1 (Fig. 8 c). 
Interestingly, expression of this construct was accompanied 
by increased apoptosis (Fig. 8 d), which is in agreement with 
the described ability of the caspase-cleaved isoform lacking the 
same domain to promote cell death (Pelizon et al., 2002). The 
expression levels of the Cdc6-COOH mutant were consider-
ably lower than those of the 125-Cdc6 mutant (Fig. 8 c), high-
lighting the importance of the C-terminal domain for both 
repressive ability and stability.
The corresponding luciferase and ChIP assays with the 
Cdc6 mutants paralleled that of E-cadherin expression analysis 
Figure 5. Cdc6 transcriptionally represses E-cadherin. (a and b) E-cadherin (E-Cad) protein (a) and mRNA (b) level reduction in MCF7A, MDCK, P1, and 
HBEC3-KT cells after transient Cdc6 expression. The asterisk denotes a statistically significant result. Error bars indicate SDs. Molecular markers are given 
in kilodaltons.
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Figure 6. Cdc6 represses E-cadherin by binding the E-boxes of the CDH1 promoter. (a) Decreased activity of the CDH1 promoter-driven luciferase reporter 
when cotransfected with Cdc6 in MCF7A cells (Table S6). The positive control was the regulatory domain (RD) of INK4/ARF. (inset) CDH1 promoter 
diagram with the E-boxes positioned (Peinado et al., 2004) and numbered as per the human CDH1 sequence (Berx and van Roy, 2009). The asterisk 
denotes a statistically significant result. hRD, human RD; hE-Cad, human E-cadherin. (b and c) Production of nascent DNA from a replication (Repl.) origin 
adjacent to the CDH1 promoter in P1 (b)- and A549 (c)-Cdc6 and corresponding Mock cells. (b) Histograms depicting the activation of a cryptic replication 
origin identified next to the promoter of the mouse CDH1 gene, in P1-Cdc6 cells, in comparison with the corresponding Mock ones. The well-established 
replication origin of the HPRT gene was used as an internal control. Transcr., transcription. (c) Histograms depicting increased activation of an already 
active replication origin identified next to the promoter of the human CDH1 gene, in A549-Cdc6 cells, in comparison with the corresponding Mock ones. 
The well-established replication origin of the Lamin B2 gene was used as an internal control (C, control region, distal origin-lacking region; O, well- 
characterized replication origin in the HPRT and Lamin B2 genes). Values are expressed as relative enrichment of the origin-containing region compared 
with the origin-lacking regions and represent five experiments ± 1 SD. Numbers next to the bars in the histograms denote fold increase. Numbers on the 
axis above the histograms denote distance in base pairs. (d) Sequence homology based on a shared consensus between the E-cadherin E-box promoter 
and the RDIKN4/ARF element in mammals (numbering as per the human CDH1 sequence; Berx and van Roy, 2009). Divergent nucleotides are colored. Note 
the rodent-specific presence of the E-pal element (E-box 2 [inverted E-box sequence]/E-box 1 sequence). (e) Luciferase assay of human CDH1 promoter 
construct with wild-type or mutated E-boxes (1, 3, and 4; Table S6) cotransfected with Cdc6 in MCF7A, P1, and induced A549–Tet-ON cells. (f) Radio-
active EMSA with a full-length human recombinant Cdc6 protein (Table S5). The triple plus sign denotes addition in excess of oligonucleotide. L, labeled 
oligonucleotide; UL, unlabeled oligonucleotide; wt, wild type; mut, mutant. Error bars indicate SDs.
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asynchronous replication of the H19/Igf2 locus, which is mono-
allelically expressed by delaying the replication of the CTCF-
bound maternal allele (Bergström et al., 2007), and to reduce 
replication fork progression at the DM1 (myotonic dystrophy 
type-1) locus (Cleary et al., 2010).
We have also identified a putative CTCF binding site within 
the RDINK4/ARF element (Gonzalez et al., 2006; Bao et al., 2008) 
We thus surmised that displacement of CTCF by Cdc6 binding 
to the E-cadherin promoter results in CDH1 silencing (Fig. 7, 
a and c), triggering activation of adjacent replication origins. 
Interestingly, we observed that silencing of CTCF, mimicking 
CTCF displacement, resulted in increased activity of the adja-
cent to the CDH1 promoter origins of replication (Fig. 9 c). In 
line with this finding, CTCF has been reported to regulate the 
Figure 7. Cdc6 triggers CDH1 promoter heterochromatinization by displacing the chromosomal insulator CTCF and the variant histone H2A.Z. (a) ChIP 
for myc-tagged Cdc6 binding to the mouse E-pal element and human E-box 1 and 3, CTCF and H2A.Z histone displacement, hypoacetylation of histones 
H3 and H4, and increase in H3K9me3 in mouse and human cells (middle box). T47D and MDA-MB-231 were used as control cell lines (Witcher and 
Emerson, 2009; similar results were obtained with the primers encompassing the 216-bp region described by Witcher and Emerson [2009]; Table S3 and 
not depicted). The RDIKN4/ARF element (PC, positive control; left box) and regions located 1.05 kb downstream of the E-pal element and 5 kbp upstream of 
the E-box (NC, negative control; top right box) were used as positive and negative controls, respectively. (bottom right box) TSA prevents Cdc6-induced 
deacetylation of the CDH1 promoter. (b) Sequence homology between mammalian E-cadherin promoter regions encompassing E-box 1. CTCF-binding 
element is highlighted in gray. Divergent nucleotides are colored. (c) CTCF silencing leads to E-cadherin transcriptional repression. Ctr si, control siRNA. 
Error bars indicate SDs. Molecular markers are given in kilobases (a) and kilodaltons (c).
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always suffice for EMT (Thiery et al., 2009). Indeed, we have 
observed that MCF7A cells stably expressing Cdc6 do not 
demonstrate features of EMT despite reduced E-cadherin levels 
(unpublished data). Interestingly, both P1 and A549 cells harbor 
mutated activated Ras (Liontos et al., 2007), a signaling pathway 
implicated in EMT (Turley et al., 2008), and it is thus likely that 
cooperation between Ras and Cdc6 composes a triggering event 
leading to EMT. In support of this hypothesis, Cdc6 overexpres-
sion cooperates with oncogenic Ras to transform mouse embryo 
fibroblasts (Gonzalez et al., 2006).
Various transcriptional repressors of E-cadherin have 
been previously described (Peinado et al., 2007). Our data 
suggest that oncogenic Cdc6 acts in a manner similar to the 
E-cadherin repressors Snail1/2, ZEB1/2, and E47, which bind 
directly to the E-boxes of the CDH1 promoter (Peinado et al., 
2007). A nodal difference between Cdc6 and Snail is that Cdc6 
confers a growth advantage in the cells that overexpress it, 
whereas Snail prevents entry into S phase by repressing cyclin 
D transcription (Vega et al., 2004). This discrepancy probably 
reflects their diverse physiological roles. Snail1 plays a vital part 
in gastrulation and neural crest development (Thiery et al., 2009), 
and by blocking S phase, it possibly synchronizes embryonic 
cell populations orchestrating the morphogenetic process. The 
periodical expression of Cdc6 secures physiological proliferation 
and found that silencing of CTCF enhances the activity of 
the replication origin previously identified within this element 
(Fig. 9 d; Gonzalez et al., 2006; Witcher and Emerson, 2009). 
Collectively, the aforementioned data suggest that the binding 
of oncogenic Cdc6 to the CDH1 locus leads to transcriptional 
repression of E-cadherin and the activation of adjacent origins 
of replication through displacement of CTCF.
Discussion
Unraveling the mechanisms that neutralize tumor suppressor 
genes is fundamental in understanding carcinogenesis. E-cadherin 
is a key adhesion molecule frequently lost, by various means, in 
a range of epithelial malignancies and is considered as a tumor 
suppressor (Hirohashi, 1998; Berx and van Roy, 2009). The 
observation that cells overexpressing Cdc6 undergo EMT was 
unexpected and led us to the discovery of a novel mechanism of 
E-cadherin transcriptional repression mediated by Cdc6. The 
prominent reciprocal relationship between high Cdc6 levels and 
reduced E-cadherin expression, in different primary human 
tumors (Fig. 3), validates the clinical significance of this poten-
tial novel cancer-promoting mechanism.
Down-regulation of E-cadherin is considered a key initi-
ating event in EMT, but sole suppression of E-cadherin does not 
Figure 8. The Walker B motif and the C-terminal domain are essential for CDH1 suppression. (a) Schematic presentation of Cdc6 mutants. Lined box 
denotes mutation of serines at codons 54, 74, and 106. N, N terminus; C, C terminus. (b) Effects of the Cdc6-WB, Cdc6-AAA, and Cdc6-125 mutants 
on E-cadherin (E-Cad) protein level in MCF7A cells. (c) Inability of Cdc6-COOH to down-regulate E-cadherin. Cdc6-COOH mutant protein levels are 
considerably lower than the Cdc6-125, indicating that the presence of the C-terminal domain is crucial for its stability. EV, empty vector. (d) Flow cyto-
metric analysis of Cdc6-COOH (Table S6)–transfected MCF7A cells depicting increased apoptosis (increased sub-G1 phase). (e) Luciferase (Luc) activity 
of the CDH1 promoter-driven luciferase reporter when cotransfected with wild-type (Wt) and Cdc6 mutants in MCF7A cells. (f) ChIP assay of the Cdc6 
mutants in MCF7A cells. The binding capacity of the mutants followed their repressive activity (e). Error bars indicate SDs. Molecular markers are given in 
kilodaltons (b and c) and kilobases (f).
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repair generated DNA lesions, but eventually, selective pres-
sure may disable its components, fuelling genomic instabil-
ity and tumor growth (Halazonetis et al., 2008; Negrini et al., 
2010). In line with this scenario, we observed allelic loss of 
p53 in both P1 and A549 cells stably expressing Cdc6. The 
acquired growth advantage could be further stimulated by the 
by disallowing the detrimental process of rereplication (Lau 
et al., 2007); however, when Cdc6 is constantly overexpressed, 
this periodicity is lost, rendering the DNA prone to rereplica-
tion (Blow and Gillespie, 2008; Borlado and Méndez, 2008). 
This form of oncogene-induced replication stress will initially 
trigger the DNA damage response checkpoint, in an attempt to 
Figure 9. CTCF displacement links Cdc6 overexpression with suppression of CDH1 and increased replication origin activity. (a) E-cadherin (E-Cad) levels 
follow the activity of the replication (Repl.) origin located in the human CDH1 promoter in induced and noninduced A549-Cdc6–Tet-ON cells (C, distal 
origin-lacking region; O, characterized Lamin B2 gene replication origin; Transcr., transcription; Falaschi et al., 2007). (b) CTCF displacement from the 
CDH1 promoter follows Cdc6 induction in A549-Cdc6–Tet-ON cells. CTCF ChIP assay in A549-Cdc6–Tet-ON cells induced and shut down at different 
time points. (c) Silencing of CTCF in A549-Mock cells activates the identified at the CDH1 locus replication origin. (d) CTCF silencing in INK4A/ARF-expressing 
MDA-MB-435 cells activates the reported adjacent replication origin (Gonzalez et al., 2006). crtsi, control siRNA. Error bars indicate SDs. Molecular 
markers are given in kilodaltons (a and c) and kilobases (b).
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It has recently been proposed that CTCF is able to form 
unusual DNA structures through its zinc finger domains, in the 
form of DNA loops (MacPherson and Sadowski, 2010). Because 
replication origins in eukaryotes are not defined by specific se-
quences but rather by structural chromatin context (Antequera, 
2004; Cvetic and Walter, 2005), it is likely that reorganization 
of these high order CTCF/chromatin structures by Cdc6 is the 
trigger for replicon activation, at least in the case of CDH1 and 
INK4/ARF loci (Fig. 10). More than 13,000 CTCF binding sites 
are mapped (Kim et al., 2007), and 104–106 replication origins 
have been suggested to occur in the genome (Cadoret et al., 2008; 
Sequeira-Mendes et al., 2009). In light of these observations, 
it would be of interest to define targets of oncogenic Cdc6 at 
genome-wide levels and determine whether a functional relation-
ship between target genes, CTCF binding, and replication origins 
exists that associates with malignant transformation. A prediction 
of this prospective network is that most Cdc6-regulated targets 
would be either cell cycle inhibitors or genes involved in differ-
entiation. In this mode, oncogenic Cdc6 would be expected to 
switch off genes that restrain cell proliferation and at the same 
time activate replication initiation. Whether the Cdc6 transcrip-
tional program interferes with other transcriptional pathways 
remains an interesting open question. In this context, it was re-
ported that Cdc6 interacts with c-myc, impeding E-box–dependent 
ability of Cdc6 to transcriptionally suppress the tumor suppres-
sor genes, p16INK4A, ARF (Gonzalez et al., 2006), and CDH1 
(this paper). These oncogenic manifestations of Cdc6 function 
may have additional repercussions. If for example, in the ap-
propriate cellular context and microenvironment, Cdc6-driven 
EMT/MET is used for invasion and metastasis, the metastatic 
(secondary) site may well resemble phenotypically the primary 
site, but the two lesions will vary genetically. Such a prospect 
should be taken into consideration in clinical practice, particu-
larly when therapeutic strategies are designed.
Results presented in this study demonstrate that Cdc6 bind-
ing to the E-boxes of the CDH1 promoter stimulates not only 
local heterochromatization but also the activation of origins of 
replication proximal to the CDH1 promoter. Increasing evidence, 
including the frequent location of replication origins near pro-
moters, points toward an interesting interplay between replica-
tion and transcription (Sequeira-Mendes et al., 2009). The 
suggested aligned organization of replicons and transcription ini-
tiation sites into functional units would be teleologically more 
effective if the coordination of such fine procedures is regulated 
by a single molecular “switch.” Our data suggest that oncogenic 
Cdc6 undertakes this role at the CDH1 locus and links transcrip-
tional repression of E-cadherin to displacement of CTCF, re-
sulting in activation of replication origins.
Figure 10. Model describing the ability of oncogenic Cdc6 to act as a molecular switch. (a and b) Cdc6 acting as a molecular switch at the CDH1 (a) and 
INK4/ARF (b) locus (see Discussion). Ori, replication origin.
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using the calcium phosphate precipitation method. The infected cells were 
selected in 350 µg/ml hygromycin B for 3 wk. All experiments were per-
formed in at least three independent replicates.
siRNAs and transient transduction–transient transfection assays
Anti-Cdc6 and anti-CTCF siRNA (Invitrogen) transfection in P1 and A549 
Cdc6 cells was performed as previously described (Liontos et al., 2009). 
In brief, for RNA silencing, 3 × 105 cells were plated in 60-mm dishes 
and, the next day, transfected using Lipofectamine 2000 (Invitrogen) with 
the appropriate RNAi pool (Stealth Select; Invitrogen) or the corresponding 
RNAi negative control (Invitrogen) according to the manufacturer’s instruc-
tions. For transient transduction, 6 × 105 A549, MCF7A, MDCK, P1, or 
HBEC3-KT cells in 60-mm dishes were infected with retroviral pBabeHyg-
hCdc6 produced in Phoenix cells and as described in the previous section 
(Liontos et al., 2007). The functional efficiency of the Cdc6 mutants was 
examined in MCF7A cells as follows: 6 × 105 cells were infected with the 
pBabeHyg-hCdc6-AAA and pBabeHyg-hCdc6-WB, whereas 8 × 105 cells 
were transiently transfected with 1 µg pCGN-hCdc6-125 and pCGN-
hCdc6-COOH using the Effectene transfection reagent following the man-
ufacturer’s instructions. Assay efficiency was estimated using the pCH110 
plasmid containing a functional lacZ gene under the control of SV40 early 
promoter (GE Healthcare). Constructs are presented in Table S6. All ex-
periments were performed in at least three independent replicates.
Scratch wound assay
Cells were seeded on 60- or 100-cm2 tissue-culture plastic dishes (Thermo 
Fisher Scientific) at 80% cell confluence, and the next day, a scratch wound 
was performed using a sterile 200-µl pipette tip. Phase-contrast images 
were taken at the starting (0 h) time point and at various time points up to 
48 h using an inverted microscope (DMIRE2; Leica). Data are presented as 
percentages of the remaining gap distance relative to the initial gap distance. 
Data from three independent measurements were averaged, and the corre-
sponding SD is also reported.
Soft agar assay
60-mm dishes were layered with 3 ml of 0.7% (wt/vol) low melting point 
agarose (SeaPlaque; Lonza) dissolved in serum-containing medium. 25 × 
103 A549 or A549/Cdc6 cells were then mixed with 1.6 ml of 0.35% 
(wt/vol) warm agar (42°C) in serum-containing medium and plated on 
the solidified agarose layer. Agar was added weekly, and cellular foci 
were enumerated on day 17. Experiments were performed in at least three 
independent replicates.
Invasion assay
A549-Mock and A549-Cdc6 stable clones were seeded on top of a matri-
gel-coated transwell (BD) at 5,000 cells per 24-well plate with serum-free 
medium. The transwells were embedded into complete (full serum) culture 
medium, and cells were allowed to invade for 24 h. At the end of the 
assay, the cells at the top side of the well were scraped, and cells (invading) 
on the bottom side of the well were stained with Giemsa, photographed, 
and counted. Data from three independent measurements were averaged, 
and the corresponding SD is also reported.
BrdU staining
Cells grown on coverslips were incubated with 10 µM BrdU labeling re-
agent for 60 min at 37°C after each treatment (Liontos et al., 2007). Cells 
with incorporated BrdU were treated and visualized by indirect immuno-
fluorescence (IF) as described in the corresponding methodology subsec-
tion (see Indirect IF; Liontos et al., 2007). Data from three independent 
measurements were averaged, and the corresponding SD is also reported.
Growth curve analysis
Growth curve analysis was performed as previously described (Liontos et al., 
2007). In brief, cells were seeded on day 0 on 60-mm Petri dishes at a density 
of 3 × 105 cells/dish. Every 3 d, up to day 30, cells were trypsinized and 
counted, and 3 × 105 cells were reseeded. The ratio of cells counted versus 
the cells seeded was estimated at every subculture, and the total cell number 
was calculated by multiplying these ratios with the number of cells seeded ini-
tially. Data from at least three independent measurements were averaged, and 
the corresponding SD is also reported.
FACS
Cells were harvested with trypsinization and centrifuged at 1,000 rpm for 
5 min at room temperature. The pellet was resuspended in 500 µl PBS, fixed 
with 80% ethanol, vortexed, and stained with 50 µg/ml propidium iodide in 
the presence of 5 mM MgCl2 and 10 µg/ml RNase A in 10 mM Tris–HCl, 
transcription by changing c-myc/max heterodimer to a max/max 
homodimer (Takayama et al., 2000). The number of activated 
origins in Cdc6-transformed cells is likely to increase, in view 
of Cdc6’s ability to trigger replication initiation when tethering 
to ectopic (i.e., nonorigin) sites (Takeda et al., 2005). Upon im-
mortalization or transformation, some origins remain unchanged, 
and others increase their activity, whereas silent origins become 
activated (Di Paola et al., 2010). In line with these observations, 
we have found that the CDH1 origin was dormant in immortal-
ized but nontumorigenic P1 cells and became active upon expres-
sion of Cdc6. In contrast, we found a background activation of 
the CDH1 origin of replication in A549 carcinoma cells that was 
further increased after expression of Cdc6. Conclusively, the on-
cogenic behavior of Cdc6, uncovered in this study, along with the 
fact that it is activated by the E2F pathway, which is commonly 
deregulated in cancer (Tsantoulis and Gorgoulis, 2005), renders 
Cdc6 a promising target for future therapeutic interventions.
Materials and methods
Cell lines
The A549 (human lung cancer), MCF7A (human breast cancer), T47D 
(human breast cancer), MDA-MB-231 (human breast cancer), MDA-MB-435 
(human breast cancer), MDCK (canine kidney epithelial), and P1 (mouse 
skin papilloma) cell lines were maintained in DME (Invitrogen) with 10% 
FCS (Invitrogen), 2 mM l-glutamine (Invitrogen), and 100 µg/ml penicillin 
and streptomycin (Invitrogen) at 37°C and 5% CO2. HBEC3-KT (immortal-
ized human bronchial epithelial cells) were cultured in keratinocyte serum-
free medium (Invitrogen) containing 50 µg/ml bovine pituitary extract and 
5 ng/ml human EGF (Invitrogen) (Sato et al., 2006 and references therein). 
Microphotographs were obtained after various treatments on an inverted 
microscope (Axiovert S100; Carl Zeiss) equipped with CP-Achromat objec-
tives and a charge-coupled device IRIS high-resolution color video camera 
(SSC-C370P; Sony), whereas the Image Pro Plus v3.0 (Media Cybernetics) 
was used as image acquisition software.
Plasmids and site-directed mutagenesis (Table S6)
pBabeHyg-hCdc6 was constructed by digesting pCS3-hCdc6 with BamHI 
and XhoI and subcloning the hCdc6-cDNA into pBabeHyg (Liontos et al., 
2007). The same insert was also cloned in the BamHI and XhoI sites of 
pTRE2Hyg (Takara Bio Inc.). pBabeHyg-hCdc6-AAA was generated by 
inserting point mutations at sites A370G, G371C, C430G, and T526G 
as previously described (Gorgoulis et al., 1998b). These mutations led to 
amino acid substitutions S54A (at A370G and G371C), S74A (C430G), 
and S106 (T526G). pBabeHyg-hCdc6-WB was generated by point muta-
tions at sites A1061C and A1064C. These mutations led to amino acid 
substitutions D284A and E285A, respectively. pCGN-hCdc6-COOH 
was generated by a point mutation at C1526G leading to an early termi-
nation codon. The expressed protein product is truncated at the C terminus 
440–560 of hCdc6.
A549-Cdc6–Tet-ON inducible system
A549 cells were transfected with the pTet-ON Advanced Vector (Takara 
Bio Inc.) using transfection reagent (Effectene; QIAGEN) following the 
manufacturer’s instructions. 800 µg/ml G418 selection was initiated 4 d 
later, and clones emerged after 3 wk. Expression of rtTA (reverse tetra-
cycline-controlled transactivator protein) in stably transfected clones was con-
firmed with immunoblot analysis (antibody TetR monoclonal; Takara Bio 
Inc.). A549 Tet-ON clones with robust rtTA expression, produced in our 
laboratory and donated by S. Krupenko (Medical University of South 
Carolina, Charleston, SC; Oleinik and Krupenko, 2003), were transfected 
in parallel with pTRE2Hyg-hCdc6. 300 µg/ml hygromycin selection was 
initiated 4 d later, and clones emerged after 3 wk. Clones with robust 
Cdc6 expression were selected.
Stable transduction
A549 cells were infected with high titer retroviruses generated following 
transfection of 40% confluent amphotropic Phoenix cells grown in Opti-
MEM (Invitrogen) with 1 µg/µl pBabeHyg and pBabeHyg-hCdc6 (Table S6) 
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Oregon green–conjugated goat anti–mouse or Texas red–conjugated goat 
anti–rabbit secondary antibody at a dilution of 1:1,000 (Invitrogen). Counter-
staining was performed with 100 ng/ml DAPI (Sigma-Aldrich). A fluores-
cence microscope (Axiolab; Carl Zeiss) equipped with a camera (AxioCam 
MRm; Carl Zeiss) and Achroplan objectives was used for microscopic ob-
servation, and image acquisition was performed with AxioVision software 
(release 4.7.1; Carl Zeiss).
Evaluation. Membranous immunopositivity for E-cadherin was evalu-
ated. For -catenin, the following staining patterns were discerned: 
(a) membranous, as a linear staining at the cell membranes, and (b) cyto-
plasmic–nuclear and/or nuclear (Kotsinas et al., 2002). Cdc6-positive im-
munoreactivity was estimated when cytoplasmic and/or nuclear staining 
was observed (Karakaidos et al., 2004).
Controls. Normal mouse skin tissue and P1 parental cells were used 
as controls for E-cadherin and -catenin immunostaining. Sections from 
previously characterized tumors served as controls for Cdc6 immunoreac-
tivity (Liontos et al., 2007). Antibodies of the corresponding IgG fraction, 
but of unrelated specificity, were used as negative controls.
Transmission electron microscopy
Exponentially growing cells were fixed in growth medium containing 2% 
formaldehyde and 2% glutaraldehyde for 10 min at 37°C, washed in PBS, 
and postfixed in 2% formaldehyde and 2% glutaraldehyde in PBS for 2 h at 
room temperature. Cells were then rinsed in PBS, fixed in OsO4, dehydrated 
in a graded series of increased concentrations of ethanol solutions, gently 
scraped off with a rubber scraper, infiltrated, and finally embedded in pure 
Epon/Araldite resin for 24 h at 60°C (Trougakos and Margaritis, 1998; 
Trougakos et al., 2001). Counterstained thin resin sections were examined 
using an electron microscope (EM 300; Philips) operating at 60 kV. Images 
are shown as raw data after brightness and contrast adjustment.
Total protein extraction, cell fractionation, and Western blot analysis
Total protein extraction. Total protein extracts were obtained by homogeni-
zation in 50 mmol/liter Hepes, pH 7.5, 150 mmol/liter NaCl, 15 mmol/
liter -mercaptoethanol, 0.5 mmol/liter phenylmethyl sulfonyl fluoride, 
and 0.1% NP-40 (Sigma-Aldrich). The homogenate was centrifuged at 
3,000 rpm (1,000 g) at 4°C for 5 min. The supernatant was collected and 
adjusted to 1 µg/ml aprotinin, 1 µg/ml leupeptin, and 1 µg/ml pepstatin A 
(Merck; Liontos et al., 2007).
Nuclear and membranous–cytoplasmic extracts. Subcellular fractions 
consisting of nuclear and membranous–cytoplasmic protein extracts were 
obtained using nuclear and cytoplasmic extraction reagents (NE-PER; 
Thermo Fisher Scientific) with protease inhibitor (benzamidine aprotinin, 
leupeptin, and phenylmethyl sulfonyl fluoride) addition according to the 
manufacturer’s instructions (Kotsinas et al., 2002).
Antibodies and controls. The following antibodies and the correspond-
ing cell extracts (controls) were used: (a) Anti-Cdc6 (DCS-180; class: IgG1 
mouse monoclonal; epitope: recombinant, full-length hCdc6; 1:1,000; Mil-
lipore). HeLa cells were used as positive controls. (b) Anti–E-cadherin (36/
E-cadherin; class: IgG2a, mouse monoclonal; epitope: human E-cadherin 
C-terminal recombinant protein; 1:5,000). A549 cells were used as 
positive controls. (c) Anti–-actin (class: IgG rabbit polyclonal; epitope: 
N-terminal residues of human -actin; 1:1,000; Millipore). (d) Anti-p53 
(1C12; class: IgG1 mouse monoclonal; epitope: residues surrounding 
Ser20 of human p53; 1:1,000; Cell Signaling Technology). Positive con-
trol was as previously described (Liontos et al., 2009). (e) Anti-p19 (class: 
IgG rabbit polyclonal; epitope: full-length mouse p19 ARF fused to GST; 
1:500; Millipore). Positive controls were mouse embryo fibroblasts. (f) Anti-
p16 (F-4; class: mouse monoclonal IgG1; epitope: amino acids 1–167 rep-
resenting full-length p16 of mouse origin; 1:500; Santa Cruz Biotechnology, 
Inc.). HeLa cells were used as positive controls.
Gel electrophoresis, blotting, and evaluation. Protein extracts were sep-
arated by SDS-PAGE and electroblotted onto membranes (Millipore), and 
results were evaluated as previously reported (Liontos et al., 2007).
DNA–RNA analysis
Isolation of DNA and RNA. For DNA extraction, cells were lysed in 50 mM 
Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, and 1% SDS in the pres-
ence of 0.1 mg/ml proteinase K until completely dissolved. DNA was ex-
tracted with phenol/chloroform and RNase (Sigma-Aldrich) digestion 
followed by ethanol precipitation (Liontos et al., 2007). For RNA isolation, 
the TRIZOL reagent (Invitrogen) was used following the manufacturer’s in-
structions. Quality and quantity of isolated nucleic acids were estimated by 
spectrophotometry, fluorometry, and gel electrophoresis.
pH 7.5. DNA content was assessed on a flow cytometer (FACSCalibur; BD). 
Data from three independent measurements were averaged, and the corre-
sponding SD is also reported in Fig. 1 (tables).
Subcutaneous tumor xenografts, assessment of growth, and tumor specimens
A549-Mock and A549-Cdc6 cells were harvested, washed in PBS, and ad-
ministered (2 × 106; n = 5) at two sites in the subcutaneous tissue of the left 
dorsal flank of 7-wk-old male SCID mice. Tumor growth was monitored and 
volume (V) was calculated using the formula: V = a × b × ([a + b]/2) × /6. 
P1-Mock– and P1-Cdc6–derived mouse tumors were obtained in a similar 
manner as previously described (Liontos et al., 2007). In brief, cells were har-
vested, washed in PBS, and subcutaneously injected (106; n = 5) at two sites 
in the abdominal region of 7-wk-old male SCID mice. Human tumors from ex-
panded sets of laryngeal, lung, and colon along with a new set of gastric 
tumors were used for immunohistochemical analysis (Liontos et al., 2007).
Tumor specimens
Formalin-fixed paraffin-embedded sections from 20 tumors, generated after 
injection of P1-Cdc6 clones in SCID mice, were analyzed. One section of each 
tumor was hematoxylin–eosin stained, and others were immunohistochemi-
cally analyzed. Formalin-fixed paraffin-embedded sections from expanded 
sets of human laryngeal, lung, and colon tumors, previously analyzed 
for Cdc6 expression (Liontos et al., 2007), and a new set of gastric tumors 
were used for immunohistochemical analysis after local ethical committee 
approval (Table S1).
Immunohistochemistry
Antibodies. The following antibodies were used: (a) anti-Cdc6 (H-304; 
class: IgG rabbit polyclonal; epitope: amino acids 257–560 of Cdc6 of 
human origin; 1:50; Santa Cruz Biotechnology, Inc.), (b) anti–E-cadherin 
(36/E-cadherin; class: IgG2a, mouse monoclonal; epitope: human E-cadherin 
C-terminal recombinant protein; 1:100; BD), (c) antipancytokeratin (80; 
class: IgG1 mouse monoclonal; 1:25; Abcam), and (d) antivimentin (class: 
IgG rabbit polyclonal; epitope: 400 amino acids to the C terminus of 
human vimentin; 1:1,000; Abcam).
Method. Immunohistochemistry was performed using a detection kit 
(Laboratory Vision Ultra; Laboratory Vision) according to the manufactur-
er’s instructions. In brief, 5-mm paraffin sections were deparaffinized by in-
cubation in xylene and rehydrated in a graded series of ethanol aqueous 
solutions. Antigen retrieval was performed with 7 mM citrate buffer, 
pH 6.0, by microwave heating the sample for 15 min. Endogenous per-
oxidase activity was blocked by incubating the slides in 3% hydrogen per-
oxide in TBS for 10 min. The primary antibodies were incubated at 4°C 
overnight and then detected using the visualization system (EnVision Plus; 
Dako). The immunoreaction was developed with DAB (Dako) for 5 min, 
and hematoxylin counterstaining was used. A microscope (DM LB; Leica) 
equipped with a digital camera (DFC320; Leica) and N Plan objectives 
was used for picture acquisition. Photos were taken with the Application 
Suite software (version 2.2; Leica) using the automatic (software) set condi-
tions for image acquisition.
Evaluation. hCdc6 positivity was ascribed when cytoplasmic 
and/or nuclear staining was observed (Karakaidos et al., 2004). Cytoplas-
mic immunoreactivity for pancytokeratin and vimentin and membranous 
immunostaining for E-cadherin were considered as positive.
Controls. Sections from previously characterized tumors (Liontos et al., 
2007) served as controls for Cdc6 immunoreactivity, whereas normal 
mouse skin was used as control tissue for E-cadherin (Fig. 1), pancytokera-
tin, and vimentin immunostaining (not depicted). Staining of normal epithe-
lial tissues was considered as an internal E-cadherin–positive control in the 
examined human tissues (Fig. 3). Antibodies of the corresponding IgG 
fraction, but of unrelated specificity, were used as negative controls.
Indirect IF
Antibodies. The antibodies used were (a) anti–E-cadherin (36/E-cadherin; 
class: IgG2a, mouse monoclonal; epitope: human E-cadherin C-terminal 
recombinant protein; 1:100), (b) anti–-catenin (E-5; class: IgG1 mouse 
monoclonal; epitope: amino acids 680–781 mapping at the C terminus of 
-catenin of human origin; 1:100; Santa Cruz Biotechnology, Inc.), 
(c) anti-Cdc6 (180.2; class: IgG1 mouse monoclonal; 1:100), and (d) anti-
BrdU (mouse monoclonal; Abcam).
Method. Indirect IF analysis was performed according to a published 
protocol (Liontos et al., 2007). In brief, IF analysis was applied to cells cul-
tured on coverslips and fixed with ice-cold methanol for 5 min. The cells 
were then incubated with primary antibodies at 4°C overnight. Subse-
quently, the antigen–primary antibody complexes were detected with an 
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360 ml, grown to OD595 of 0.6, supplemented with 0.5 mM IPTG, and 
grown for another 3 h at 37°C. After IPTG induction, cells were harvested 
and stored at 80°C.
Purification of His(6)-Cdc6. Purification of native His(6)-Cdc6 was 
performed with Co2+-substituted metal affinity resin according to slightly 
modified manufacturer’s instructions (TALON; Takara Bio Inc.). In brief, the 
bacterial pellet obtained from 180 ml culture was thawed and resuspended 
in 8 ml equilibration/wash buffer (50 mM sodium phosphate and 300 
mM NaCl). Lysozyme was added to a final concentration of 0.75 mg/ml. 
After incubation at room temperature for 30 min, bacterial lysates were 
sonicated, and cell debris was removed from the lysate by centrifugation. 
The supernatant was incubated with 0.8 ml Co2+-substituted metal affin-
ity resin and preequilibrated in equilibration/wash buffer. The resin was 
sedimented and washed three times with equilibration/wash buffer and 
once with preelution buffer (50 mM sodium phosphate, 300 mM NaCl, 
and 20 mM imidazole). Bound proteins were eluted with the same buffer 
containing 450 mM imidazole. Fractions containing native His(6)-Cdc6 
were identified by SDS-PAGE.
EMSA
Nuclear extracts were obtained using the nuclear and cytoplasmic ex-
traction kit (NE-PER) as per the manufacturer’s instructions. Radioactive 
EMSAs were performed as previously described (Gorgoulis et al., 
1998b). In brief, 1 ng -[32P]ATP end-labeled oligonucleotides (Fig. S4) 
and 4 µl P1 or A549 whole-cell extracts were incubated for 10 min 
to activate specific DNA binding of Cdc6 protein. Competition experi-
ments were performed by preincubating activated extracts with a 50-fold 
molar excess of the corresponding unlabeled oligonucleotides (Fig. S4). 
For supershift experiments, preincubations were performed with 100 ng 
anti-Cdc6 antibody (C42F7; class: IgG rabbit monoclonal; Cell Signal-
ing Technology). Protein–DNA binding reactions were resolved on a 4% 
nondenaturing polyacrylamide gel followed by exposure of the dried gel 
to x-ray film. For comparison reasons, oligonucleotides comprising the 
E-box 1 (Table S5) for both human and mouse CDH1 promoter were 
used. Selection of E-box 1–spanning oligonucleotides was also based on 
the coincidence with a CTCF binding site (Binding of Cdc6 to the E-boxes 
displaces the chromosomal insulator CTCF and histone H2A.Z triggering 
CDH1 promoter heterochromatization in Results and Fig. 7 b) as well as 
with the mouse E-pal element.
ChIP assay
3 × 106 MCF7A cells transiently transfected with the corresponding Cdc6 
constructs (wild type and mutants), 3 × 106 A549 cells transiently trans-
fected with wild-type Cdc6, and 3 × 106 cells from corresponding P1-Cdc6 
stable cell lines were cross-linked with 1% formaldehyde for 10 min at 
37°C. Cross-linking was stopped by the addition of glycine to a final con-
centration of 125 mM for 5 min at 37°C. Cross-linked cells were washed 
twice in ice-cold PBS and scraped in 1 ml PBS containing protease and 
phosphatase inhibitors. Cells were collected by centrifugation for 5 min 
at 2,000 rpm, and the pellet was resuspended in 600 µl buffer (50 mM 
Tris-HCl, pH 8.0, 85 mM KCl, and 0.5% NP-40) and incubated for 10 
min on ice. The lysate was centrifuged for 5 min at 5,000 rpm, and the 
pellet was resuspended in 600 µl lysis buffer (50 mM Hepes-KOH, pH 7.5, 
150 mM NaCl, 1 mM EDTA, pH 8.0, 1% Triton X-100, 0.1% sodium 
deoxycholate, and 0.1% SDS) containing protease and phosphatase in-
hibitors. Lysates were sonicated to shear DNA to a mean fragment size of 
500–1,000 bp. The debris was pelleted by 5-min centrifugation at 13,000 
rpm at 4°C, and the soluble chromatin material was precleared with salmon 
sperm DNA/50% protein A agarose slurry (Millipore). The antibodies 
used for the immunoprecipitation were (a) anti- H3K9me3 (class: rabbit 
polyclonal IgG; Millipore), (b) antiacetyl–histone H3 (Lys9; class: rabbit 
polyclonal IgG; Millipore), (c) antiacetyl–histone H4 (class: rabbit poly-
clonal IgG; Millipore), (d) antimyc tag (9B11; class: mouse monoclonal 
IgG2A; Cell Signaling Technology), (e) anti-HA tag (ChIP Grade; class: 
rabbit polyclonal IgG; Abcam), (f) anti-CTCF (class: IgG rabbit polyclonal 
against amino acids 659–675 [CTNQPKQNQPTAIIQVED] of human 
CTCF [CCCTC-binding factor]; Millipore), and (g) anti-H2A.Z (ChIP Grade; 
Abcam; a gift from A.R. Nebreda, Institute for Research in Biomedicine 
Barcelona, Barcelona, Spain). After overnight incubation, the immune com-
plexes were harvested with 60 µl salmon sperm DNA/50% protein A aga-
rose slurry for 2 h at 4°C. The beads were washed sequentially for 5 min 
each at room temperature in 1 ml lysis buffer without SDS, in 1 ml lysis buf-
fer plus 500 mM NaCl, in 1 ml of buffer (10 mM Tris-HCl, pH 8.0, 1 mM 
EDTA, pH 8.0, 250 mM LiCl, 1% NP-40, and 1% sodium deoxycholate), 
and finally twice in TE (Tris-EDTA). Immune complexes were eluted with 
cDNA preparation. For reverse transcription, 2 µg total RNA was re-
verse transcribed with oligo-dT (Invitrogen) and 200 U Moloney murine 
leukemia virus reverse transcription (Invitrogen) according to the manufac-
turer’s instructions (Liontos et al., 2007).
Real-time RT-PCR
Assessment of E-cadherin levels. Real-time RT-PCR was performed to examine 
the E-cadherin mRNA levels in A549, MCF7A, MDCK, P1, and HBEC3-KT 
cells using -microglobulin as a reference (Table S3; Liontos et al., 2007).
Real-time PCR quantification of nascent-strand DNA. Nascent-strand 
DNA was quantified with the real-time PCR system (LightCycler 480 Instru-
ment II) using the SYBR Green I Master kit (LightCycler 480; Roche) ac-
cording to the manufacturer’s instructions. PCR reactions were performed 
in 20 µl as previously described (Giacca et al., 1994; Rampakakis et al., 
2008). Sequences and amplification conditions for all primer sets are listed 
in Table S4. Nonreplicating DNA from serum-starved A549 or P1 cells 
was included to create a standard curve for the quantification of the PCR 
products. A negative control without template DNA was also included.
Isolation of nascent-strand DNA
The method applied has been previously described and extensively used 
with certain modifications (Tao et al., 2001; Sibani et al., 2005a,b; 
Callejo et al., 2006; Di Paola et al., 2006, 2010; Rampakakis et al., 
2008). All DNA treatments were performed under DNase-free conditions 
including the use of DNase (and RNase)-free water, tubes, equipment, 
etc., excluding the contamination by DNases. Furthermore, the identifica-
tion of the cryptic origin at the CDH1 locus was performed upon mapping 
a 10-kb region flanking the CDH1 promoter, wherein no other origins 
were detected.
Shearing of the DNA was optimized to produce DNA of 20– 
30 kb (Di Paola et al., 2006) and not completely fragmented DNA. In this 
manner, the long parental DNA was sheared, whereas the short nascent 
DNA is not (or minimally). Identical results were obtained with either the 
aforementioned modified  exonuclease method or the nascent-strand ex-
trusion method, which did not involve DNA shearing (Tao et al., 2001). 
The technique was optimized to ensure an efficient  exonuclease diges-
tion. Under these conditions (Di Paola et al., 2006), any DNA that was not 
RNA primed (including an internal linear control—linearized pCR-XL-TOPO 
plasmid) was digested away. The methylene blue staining was used to 
stain the DNA markers to be able to excise and size select the 350- and 
1,000-bp region containing the nascent strands.
Luciferase reporter assay
MCF7A, P1, and induced A549-Cdc6 Tet-ON cells were seeded in 96-
well plates at 2,000 cells per well with 100 µl DME. Cells at a 90% conflu-
ency were transfected using 50 µl Opti-MEM reduced-serum medium, 1 µl 
Lipofectamine 2000 (Invitrogen), 0.2 µg plasmid pGL2Basic, pGL2Basic-
Ecad3/luciferase, pGL2Basic-EcadK1, or pGL2Basic-EcadK1/EpalMUT/
EboxMUT/Ebox2MUT (Ji et al., 1997), and 0.2 µg of the corresponding 
pCGN Cdc6 constructs or pCGN without an insert (Table S6). Cell extracts 
were obtained as recommended by the manufacturer (Luciferase Assay Sys-
tem; Promega). Luciferase activities were measured in a microplate reader 
(Safire2; Tecan). Transfection efficiency was estimated using the pCH110 
plasmid containing a lacZ gene expressed under the control of the SV40 
early promoter (GE Healthcare). All transfections were repeated three times.
Recombinant hCdc6 production
Cloning of hCdc6. Cdc6 cDNA was amplified by PCR using Pyrococcus furiosus 
DNA polymerase (Agilent Technologies) from a human cDNA library. Am-
plification primers were 5-ATATTGCTAGCATGCCTCAAACCCGATCC-3 
(forward) and 5-GTATGCCTCGAGTTAAGGCAATCCAGTAGCTAAGA-3  
(reverse). Forward and reverse primers were designed to incorporate NheI 
and XhoI sites at the 5 and 3 end of the amplification product, respec-
tively. The product was NheI–XhoI double digested and ligated into the 
corresponding polylinker site of a dephosphorylated pET28b (EMD) vector. 
The generated pET28bh-Cdc6 construct contained hCdc6 fused in frame 
with an upstream vector sequence coding for a stretch of six histidines fol-
lowed by a thrombin cleavage site (LVPRGS).
Expression of His(6)-Cdc6. Expression of His(6)-hCdc6 was performed 
in the Escherichia coli strain BL21(DE3) (EMD) and cotransformed with 
pET28bh-Cdc6 and pMBL19-ArgU plasmids (Dieci et al., 2005). Single 
colonies of double transformants were inoculated into 50 ml lysogeny 
broth medium supplemented with 100 µg/ml ampicillin plus 50 µg/ml kana-
mycin and grown overnight at 37°C. The overnight culture was diluted with 
lysogeny broth medium supplemented with antibiotics to a final volume of 
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Nutlin treatment
P1-Mock and P1-Cdc6/wild-type stable cell lines were treated for 48 h 
with two different concentrations of nutlin-3A (Sigma-Aldrich), 5 and 
10 µM. All controls were treated with DMSO. Cells were collected for 
FACS analysis.
Loss of heterozygosity (LOH) analysis
By exploiting a 15-bp difference in the p53 gene between Mus spretus 
versus Mus musculus in P1 cells (Burns et al., 1991), we designed primers 
to perform LOH analysis. The size of the PCR product was 134/149 bp. 
In the A549 cells, we interrogated the intronic p53 D17S179E penta-
nucleotide microsatellite marker for LOH analysis as previously described 
(Liontos et al., 2009). PCR reactions were performed in a final volume of 
30 µl containing 1.5 mM MgCl2, PCR buffer (Invitrogen), a 0.2-mM con-
centration of each deoxyribonucleotide triphosphate, 1 U recombinant 
Taq polymerase (Invitrogen), and 0.3 mM primers. Primers and cycling 
conditions for LOH analysis in the mouse and human cell lines are de-
scribed in Table S3.
Conventional LOH analysis. PCR products were electrophoretically 
separated on 10% polyacrylamide gels and stained with silver nitrate as 
previously reported (Gorgoulis et al., 1998a).
Capillary electrophoresis. The PCR products were subsequently ana-
lyzed by capillary chip electrophoresis on a microfluidics-based platform 
(2100 Bioanalyzer; Agilent Technologies) for further validation.
Evaluation. LOH was determined by densitometry, comparing the 
allelic ratio of the Mock DNA against that of the corresponding clones. 
A reduction of one of the alleles in the clones was considered to repre-
sent LOH. Alterations were confirmed by performing independent dupli-
cate reactions.
Statistical analysis
Statistical analysis, comprising 2, t test, analysis of variance, and Mann–
Whitney tests, was performed with SPSS (version 12.0; IBM). Results were 
considered significant for P < 0.05.
Online supplemental material
Fig. S1 shows that Cdc6 overexpression induces genetic alterations (ge-
nomic instability) in P1 and A549 cells and representative results from mouse 
P1 cells. Fig. S2 shows representative results showing the Cdc6-induced 
genomic instability in A549 cells and p53 aberrations in the P1 and A549 
cells. Fig. S3 shows production of nascent DNA from a replication origin ad-
jacent to the CDH1 promoter in A549- and P1-Cdc6 cells. Fig. S4 depicts 
production and purification of human recombinant Cdc6 as well as EMSAs 
with whole-cell extracts. Table S1 shows a summary of clinicopathological 
and demographic data of patients used in the current analysis. Table S2 
shows immunohistochemical status of E-Cadherin and Cdc6 of the exam-
ined human carcinomas. Table S3 shows primers and annealing tempera-
tures used in real-time RT-PCR, ChIP, and LOH analyses. Table S4 shows 
sequence, percentage of GC content, melting temperature, and amplicon 
size for all E-cadherin primers used in nascent DNA analysis. Table S5 
shows oligonucleotides used in electrophoretic mobility shift assays. Table S6 
shows the vectors used in this study. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.201108121/DC1.
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200 µl (two times of 100 µl each) elution buffer (1% SDS, 50 mM Tris-HCl, 
pH 7.5, and 10 mM EDTA) and incubated for 5 min at 65°C. The pooled 
eluates were incubated with RNase for 1 and 4 h with proteinase K at 
65°C. DNA was extracted by phenol/chloroform and precipitated with 
10 µg glycogen and ethanol overnight at 20°C. The DNA was resuspended 
in 10 µl TE. DNA from the precipitated complexes was amplified by PCR. 
A 250-bp fragment of the mouse E-pal element in the E-cadherin promoter 
was amplified with the following primers: 5-TAGGAAGCTGGGAAG-3 
(forward) and 5-TGCGGTCGGGCAGGG-3 (reverse; Peinado et al., 
2007). A 93-bp fragment encompassing the human E-box elements 1 and 
3 in the E-cadherin promoter was amplified with the following primers: 
5-CTCCAGCTTGGGTGAAAGAG-3 (forward) and 5-GGGCTTTTACACTT-
GGCTGA-3 (reverse; Vesuna et al., 2008). In addition to these primers, 
in the T47D and MDA-MB-321 cell lines, a wider region of 216 bp was 
also amplified as a control for CTCF and H2A.Z binding (Table S3) as 
previously described (Witcher and Emerson, 2009). As inputs, we used 
products that corresponded to PCR reactions containing 1% of the total 
chromatin extract used in the immunoprecipitation reactions. All PCR am-
plifications were performed according to the following cycling conditions: 
35 cycles at 94°C for 40 s, 58 or 65°C for 40 s, and 72°C for 40 s with 
DNA polymerase (GoTaq Flexi; Promega). To investigate the modification 
status of histones at the E-cadherin promoter, additional ChIP assays were 
performed in cells with or without 300 nM TSA treatment for 24 h.
Comet assay
Comet assay was performed as previously described (Georgakilas et al., 
2010). In brief, 105 A549-Mock and A549-Cdc6 cells were seeded in 
60-mm dishes. 2 d later, cells were trypsinized, centrifuged, resuspended 
in 2 ml PBS, and kept on ice for 10 min. Viable cells were counted using 
Trypan blue, and PBS was added to adjust the number of cells to 100,000 
in 500 µl PBS. 50 µl PBS-containing cells were then mixed with equal 
volume of low melting agarose 1.7% (wt/vol) and were embedded in 
plugs. Plugs were subsequently incubated in 50 ml lysis solution (100 mM 
Tris-HCl, 100 mM EDTA, and 2.5 M NaCl, pH 10, with the addition of 
1% [vol/vol] Triton X-100 and 10% [vol/vol] DMSO, before use) for 1 h 
on ice and in the dark. After completion of lysis, plugs were washed twice 
in TBE (Tris–boric acid–EDTA) for 1 h on ice in the dark. Finally, plugs 
were washed and subsequently incubated in ice-cold alkaline denaturation 
buffer (300 mM NaOH and 1 mM EDTA, pH 13) for 45 min on ice in the 
dark. For electrophoresis, plugs were mounted onto 1% agarose-coated 
slides that were placed into a 30-cm horizontal constant-field gel electro-
phoresis chamber in ice-cold alkaline denaturation buffer for 20 min at 
0.7 V/cm and at 4°C. After electrophoresis, slides were dehydrated in 
ice-cold ethanol (100%) for 10 min and then allowed to dry in the dark. 
24 h later, slides were rehydrated in 5 ml of deionized water for 10 min, 
and 40 µl of diluted SYBR green (Invitrogen) was applied on each plug. 
Cells were observed under a fluorescence microscope (Axiolab) equipped 
with a monochrome UV camera (XC-EU50 CE; Sony). Analysis was con-
ducted using the CometScore software (TriTek Corp.).
Cytogenetic analysis
Mouse and human cell cultures of high mitotic index were exposed to 
0.1 µg/ml colcemid (Invitrogen) for 1 h at 37°C and harvested according 
to routine cytogenetic protocols. Chromosome preparations were stained 
with appropriate FISH probes and counterstained with Vectashield contain-
ing DAPI (0.6 µg/ml final concentration; Vector Laboratories). For the con-
struction of representative karyotypes, we combined inverted DAPI banding 
and multicolor FISH (M-FISH). M-FISH was performed in 10–25 metaphase 
plates per cell line according to the MetaSystems. Telomere-specific peptide 
nucleic acid hybridization was performed using Cy3-labeled (CCCTAA)n 
peptide nucleic acid (analogue: 2-deoxyoligonucleotide N3–P5 phos-
phoramidate) probes (Dako) following the manufacturer’s instructions. 
Molecular cytogenetic analyses were performed at 650× magnification 
using the Isis software (MetaSystems) and a microscope (Axio Imager.Z1; 
Carl Zeiss) equipped with a set of six fluorochrome filters. For the evalu-
ation of structural and numerical aberrations in P1-Cdc6 cells, we fully 
karyotyped two rounds of 50 complete M-FISH–stained metaphases from 
either Mock (pBabe) or stably Cdc6-overexpressing cells. For the evalua-
tion of random chromosome instability in A549 cells, we fully karyotyped 
two rounds of 25 complete M-FISH–stained metaphases from either Mock 
(pBabe) or stably Cdc6-overexpressing cells and from the A549-Cdc6– 
Tet-ON or –Tet-OFF cell lines grown for 60 d in vitro. Comparative karyo-
typic analyses were performed for each pair of homologous chromosomes 
of the human karyotype, and all detectable structural aberrations per pair 
were scored. Numerical chromosomal instability was evaluated through 
intraploidy chromosome gains per chromosome pair.
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